NCT01960179 - Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

361

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

lixisenatide AVE0010

Pharmaceutical form:solution Route of administration: Subcutaneous injection

Trial Locations (30)

Investigational Site Number 392006, Adachi-Ku

Investigational Site Number 392005, Chiba

Investigational Site Number 392010, Chiyoda-Ku

Investigational Site Number 392003, Chuoh-Ku

Investigational Site Number 392004, Chūōku

Investigational Site Number 392015, Chūōku

Investigational Site Number 392012, Ebina-Shi

Investigational Site Number 392024, Higashiosaka-Shi

Investigational Site Number 392023, Kashiwara-Shi

Investigational Site Number 392008, Kawagoe-Shi

Investigational Site Number 392009, Kisarazu-Shi

Investigational Site Number 392002, Koganeishi

Investigational Site Number 392007, Koriyama-Shi

Investigational Site Number 392011, Mitaka-Shi

Investigational Site Number 392025, Nagoya

Investigational Site Number 392026, Nagoya

Investigational Site Number 392013, Ogawa-Machi, Hikigun

Investigational Site Number 392014, Ohta-Ku

Investigational Site Number 392022, Okawa-Shi

Investigational Site Number 392021, Osaka

Investigational Site Number 392028, Osaka

Investigational Site Number 392029, Osaka

Investigational Site Number 392030, Sapporo

Investigational Site Number 392018, Sendai

Investigational Site Number 392001, Shinjuku-Ku

Investigational Site Number 392020, Suita-Shi

Investigational Site Number 392017, Toshima-Ku

Investigational Site Number 392027, Toyonaka-Shi

Investigational Site Number 392016, Yokohama

Investigational Site Number 392019, Yokohama